BioNeutral Group, Inc

CIK:0001427030|SEC Filings

Condensed Consolidated Statements of Operations (Unaudited) (USD $)	3 Months Ended		9 Months Ended
	Jul. 31, 2014	Jul. 31, 2013	Jul. 31, 2014	Jul. 31, 2013
Statements Of Operations [Abstract]
Revenues	$ 8,861	$ 3,310	$ 30,093	$ 4,950
Cost of Revenues	3,068	1,174	14,022	1,732
Gross Profit	5,793	2,136	16,071	3,218
Operating Expenses
Depreciation and Amortization	177,234	177,234	531,702	531,702
Salaries	237,657	266,737	569,343	590,544
Consulting Expense	91,050	252,417	337,435	472,890
Legal and Accounting Expenses	191,797	48,740	424,792	316,759
Other Selling, General and Administrative Expenses	275,595	84,165	626,409	429,271
Total Operating Expenses	973,333	829,293	2,489,681	2,341,166
Loss from Operations	(967,540)	(827,157)	(2,473,610)	(2,337,948)
Other Income (Expense)
Interest Expense	(275,180)	(34,131)	(913,817)	(100,268)
Consulting Fee Reimbursement - Vinfluence Settlement				238,750
Amortization of debt discount	(270,865)	(212,920)	(464,248)	(425,281)
Change in Fair Value of Derivative Liability	241,521	(29,356)	928,822	95,250
Total Other Expense	(304,524)	(276,407)	(449,243)	(191,549)
Net Loss Before Income Taxes	(1,272,064)	(1,103,564)	(2,922,853)	(2,529,497)
Provision for Income Taxes
Net Loss	(1,272,064)	(1,103,564)	(2,922,853)	(2,529,497)
Loss Attributable to Non-controlling Interest	107,362	93,095	270,686	213,445
Net Loss Attributable to BioNeutral Group, Inc.	$ (1,164,702)	$ (1,010,469)	$ (2,652,167)	$ (2,316,052)
Net Loss Per Common Share - Basic and Diluted	$ (0.01)	$ (0.01)	$ (0.01)	$ (0.02)
Weighted Average Number of Common Shares outstanding Basic and Diluted Loss per Share	3,153,678,075	149,565,330	1,642,430,500	135,968,202

Condensed Consolidated Statements of Cash Flows (Unaudited) (USD $)	9 Months Ended
	Jul. 31, 2014	Jul. 31, 2013
CASH FLOWS FROM OPERATING ACTIVITIES
Net Loss	$ (2,922,853)	$ (2,529,497)
Adjustments to Reconcile Net Loss To Net Cash Used in Operating Activities
Stock Based Compensation		481,315
Depreciation and Amortization	531,702	531,702
Issuance of Stock related to professional services	110,000	20,342
Interest added to promissory notes	246,800	83,575
Change in fair value of derivative liability	(928,822)	(95,250)
Amortization of debt discount	464,248	425,281
Settlement of Consulting Expense - Vinfluence Settlement		(238,750)
Changes in Operating Assets and Liabilities
Accounts receivable	6,459	(1,259)
Inventory	2,371	(16,679)
Other Assets		11,996
Accounts Payable and Accrued Expenses	1,777,021	706,165
Related Party Payables	1,554	14,186
NET CASH USED IN OPERATING ACTIVITIES	(711,520)	(606,874)
CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds from Convertible Promissory Notes	792,500	614,000
Repayments of Convertible Promissory Notes	(65,324)
NET CASH PROVIDED BY FINANCING ACTIVITIES	727,176	614,000
NET INCREASE IN CASH	15,656	7,126
CASH, BEGINNING OF PERIOD	702	676
CASH, END OF PERIOD	16,358	7,802
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION
Cash paid for Interest	22,824
Cash paid for Income Taxes
SUPPLEMENTAL DISCLOSURE OF NON-CASH INFORMATION
Return of shares and re-establishment of accrued compensation	(151,013)
Non-cash settlements of Accounts Payable and Accrued Expenses	62,950	57,826
Shares issued to escrow as security for transaction fees	10,000
Non-cash conversion of promissory note to common stock	849,853	223,115
Aggregate fair value of derivative liabilities issued	1,394,634	277,957
Non-cash settlement with Vinfluence		$ 1,331,999

Liquidity and Financial Condition (Details) (USD $)	3 Months Ended		9 Months Ended
Liquidity and Financial Condition (Details) (USD $)	Jul. 31, 2014	Jul. 31, 2013	Jul. 31, 2014	Jul. 31, 2013	Oct. 31, 2013	Oct. 31, 2012	Jul. 09, 2014 JMJ Financial [Member]
Liquidity and Financial Condition (Textual)
Convertible promissory note	$ 985,120		$ 985,120		$ 358,883		$ 250,000
Convertible promissory note amount received from related party							60,000
Working capital	(5,394,545)		(5,394,545)
Net loss	(1,272,064)	(1,103,564)	(2,922,853)	(2,529,497)
Accumulated Deficit	(60,541,242)		(60,541,242)		(57,889,075)
Cash	16,358	7,802	16,358	7,802	702	676
Cash used by operations			(711,520)	(606,874)
Proceeds from issuance of convertible debentures			792,500	614,000
Amount of additional capital require	$ 2,000,000		$ 2,000,000